Combination of biomarkers for the prognosis of response or non-response to an anti-HCV treatment
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 30, 2018
Issued Date -
N/A
app pub date -
Feb 9, 2012
filing date -
Feb 9, 2011
priority date (Note) -
In Force
status (Latency Note)
Importance
Loading Importance Indicators... 
Abstract
The application concerns means for predicting whether a subject infected with one or more HCVs has a high probability of responding to an anti-HCV treatment which will comprise the administration of interferon and of ribavirin or whether, in contrast, that subject has a high probability of not responding to that anti-HCV treatment. The means of the invention in particular involve assaying the levels of expression of selected genes, said selected genes being:
- at least one gene from among MBL2, LGALS3BP and IL8, andat least one gene from among G1P2, CCL21 and CXCL10, andoptionally, at least one gene from among AFP, CRP, CXCL11, CXCL6, CXCL9, FGF7, MDK, MMP2, SFN, TGFB2 and VEGFD.
First Claim
Other Claims data not available
Family
Loading Family data...
International Classification(s)
- 2012 Application Filing Year
- C12Q Class
- 2418 Applications Filed
- 1732 Patents Issued To-Date
- 71.63 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 0 Citation Count
- C12Q Class
- 0 % this patent is cited more than
- 7 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Jul 30, 2025 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Jul 30, 2029 |
